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Abstract
Background: Quality control (QC) and evaluation of HIV rapid test procedures are an important aspect of HIV prevention
trials. We describe QC and performance of two rapid tests, Determine
TM and Uni-Gold
TM used in a microbicide clinical trial in
rural KwaZulu-Natal, South Africa.
Methods/Results: Internal QC of both HIV rapid tests was conducted at the trial site using a Uni-Gold control kit (Uni-
Gold
TMRecombigenH HIV). Both assays produced the expected results for a total of 4637 QC tests. Study participants were
tested for HIV at screening and, if enrolled, at regular time points throughout the study. Positive or discordant results were
confirmed by a double HIV immunoassay testing strategy at a local laboratory. Overall, 15292 HIV rapid test were
performed. Sensitivity and specificity of Determine was 98.95% (95% CI: 97.72–99.61) and 99.83% (95% CI: 99.70–99.91)
respectively [positive predictive value (PPV) 97.91% (95% CI: 96.38–98.92)], for Uni-Gold it was 99.30% (95% CI: 98.21–99.81)
and 99.96% (95% CI: 99.88–99.99) respectively [PPV 99.47% (95% CI: 98.46–99.89)].
Conclusions: The results suggest that a Uni-Gold control kit can be used for internal QC of both Uni-Gold and the HIV-1
component of the Determine rapid tests. Both rapid tests performed proficiently in the trial population.
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Introduction
The Africa Centre for Health and Population Studies was one
of six research centres participating in the Microbicides
Development Programme (MDP) 301 phase III clinical trial
[1]. The trial evaluated the effectiveness and safety of PRO2000/
5 microbicide gel in the prevention of vaginally acquired HIV
infection. The trial results and details of HIV seroconversion have
been presented elsewhere [2,3]. The Africa Centre is situated in
the predominantly rural Umkhanyakude district of northern
KwaZulu-Natal where HIV prevalence is 27% in female
residents aged 15 to 49, peaking at 51% in 25 to 29 year old
women [4,5]. HIV incidence among women aged 15 to 49
remains high (4.4 per 100 person-years) [6]. Trial eligibility
criteria required women to be HIV negative at screening. Two
rapid tests were used to determine HIV status: Determine
TMHIV-1/
2 (Abbott LaboratoriesH, Tokyo, Japan, now marketed by
Inverness Medical as Alere Determine
TM) and Uni-Gold
TMHIV
(Trinity Biotech, Ireland). We evaluated a Uni-Gold control kit
(Uni-Gold
TMRecombigenH HIV) comprised of HIV-1 positive and
negative serum on Determine rapid tests. The kit is available for
internal quality control (QC) in conjunction with the Uni-Gold
rapid test. There is no dedicated control kit for the Determine test
and no evidence in the literature of a previous evaluation of the
Uni-Gold control kit for use with other HIV rapid tests. We also
assessed the performance of both HIV tests in our trial population
as some rapid tests show geographical variation of performance
or vary when used in the field by non-laboratory staff [7,8]. The
data provided by the test manufacturers shows a sensitivity and
specificity on serum and plasma specimens of 99.91% (95% CI:
99.51–100) and 98.16% (95% CI: 97.49–98.69) respectively for
the Determine rapid tests and a sensitivity and specificity of 100%
(95% CI: 95.5–100 and 97.9–100) for Uni-Gold on whole blood.
The Determine rapid test has previously been evaluated in
primary health and community clinics in South Africa [7,9] and
various settings in other countries on the continent showing
sensitivities ranging from 60.5% to 100% and specificities
between 98.9% and 100% [10–12]. In a further study conducted
in South Africa, sensitivity and specificity of the Determine assay
were 100%, for the Uni-Gold assay they were 97% and 100%
respectively when performed by trained technologists in a
laboratory setting [13].
Ethics statement
Approval was obtained from the Biomedical Research Ethics
Committee, University of KwaZulu-Natal (approval number
T111/05). Written informed consent was obtained from all
participants involved in the study.
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Both HIV rapid tests have a procedural control, or control line,
included in the test. In addition, internal QC of both rapid tests
was performed daily by nurses or HIV counsellors in compliance
with Good Clinical Laboratory Practice guidelines using the Uni-
Gold HIV-1 negative and positive control serum kit. This was
done to ensure that the assays were correctly identifying HIV-1
antibody negative and positive samples. The procedures were
recorded on QC worksheets and data from all worksheets
completed at three MDP trial clinics were analysed to verify assay
accuracy (March 2006 to August 2009). Study volunteers were
tested on whole blood (finger prick) at screening and, if enrolled, at
12, 24, 40 and 52 weeks after enrolment using the two rapid tests
in parallel. The tests were conducted at the clinics by trained
counsellors according to manufacturer’s instructions. Positive or
discordant results on either test were confirmed by a double HIV
immunoassay (IA) parallel testing strategy at the local virology
laboratory [first line: VironostikaH HIV-1 Microelisa System (Biome ´r-
ieux, Durham, North Carolina, USA), used from March 2006 to
December 2007 when discontinued by manufacturer, then from
January 2008 to August 2009: SD BIOLINE HIV 1/2 3.0 (Standard
Diagnostics, Inc. Kyonggi-do, Korea); second line: Genetic
Systems
TM rLAV EIA (Bio-Rad Laboratories, Redmond, Washing-
ton, USA)]. Venous blood was collected into SST and EDTA
tubes at the study clinics and processed within 24 hours of
drawing. Serum obtained from the SST was centrifuged within
6 hours of collection and stored at minus 80 degrees Celsius.
EDTA tubes were centrifuged and plasma and buffy coat were
obtained for storage at minus 80 degrees Celsius after a plasma
aliquot was allocated for IA testing. In addition, 5% of all negative
samples were randomly re-tested for the duration of the study by
the local laboratory. This was defined as the external QC
procedure. Sensitivity and specificity of the HIV rapid tests and
the 95% confidence interval around the estimate were calculated
in STATA by producing summary statistics for diagnostic tests
compared to true disease status [14]. The calculations were based
on the total number of true positives (HIV positive rapid
confirmed positive on IA), false positives (HIV positive rapid
found negative on IA), false negatives (HIV negative rapid found
positive during random 5% QC) and true negatives (dual negative
HIV rapids). These results were then compared to the data
provided by the test manufacturers.
Results
The Africa Centre MDP site screened 1775 women [mean age
33.4 (SD 11.1), median age 32 (IQR 23–43), ranging from 17 to 75
years] of which 1177 were enrolled. In total 4637 internal QC tests
were conducted at the clinics on both HIV rapid tests using the
Uni-Gold QC kit (n=2306 with positive serum, n=2331 with
negative serum). Both assays produced the expected results for all
QC tests. Overall, 15292 HIV rapid tests were performed on 1775
trial volunteers. Dual IA confirmation of positive and discordant
rapid tests is shown in Table 1. Sensitivity and specificity of
Determine was 98.95% (95% CI: 97.72–99.61) and 99.83% (95%
CI: 99.70–99.91) respectively [positive predictive value (PPV)
97.91% (95% CI: 96.38–98.92)], for Uni-Gold it was 99.30%
(95% CI: 98.21–99.81) and 99.96% (95% CI: 99.88–99.99)
respectively [PPV 99.47% (95% CI: 98.46–99.89)]. It is important
to note however, that double negative rapid results were accepted
as HIV negative and not confirmed by IA (unless randomly
selected for external QC), we have therefore not presented the
negative predictive value and this might have led to an over-
estimation of test sensitivity. The negative samples selected for
external QC were all confirmed negative at the local laboratory.
Discussion
These results suggest that the Uni-Gold
TMRecombigenH HIV QC
kit is useful as an internal quality control tool in a clinical setting
not only for the Uni-Gold assay for which it is certified, but also for
the Determine (HIV-1) rapid test. Further evaluation would be
necessary to assess whether it is adequate for quality control of the
HIV-2 component of the Determine rapid test. The Determine
assay demonstrated a slightly lower sensitivity and a statistically
significant higher specificity compared to the data provided by the
manufacturer. Sensitivity and specificity of the Uni-Gold test were
marginally lower. Overall, both Determine and Uni-Gold
performed proficiently under field conditions in the trial area [15].
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